SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending after securing a prime contract position in the U.S. Missile Defense Agency's SHIELD program, which is part of the Golden Dome strategy. The community is buzzing, interpreting this as a significant de-risking event that validates the company's unique dual-use satellite technology for both commercial and national security applications. This has fueled strong bullish sentiment, with many anticipating further upside driven by potential short covering.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is actively trending amid significant investments in AI infrastructure, highlighted by a new multi-billion dollar partnership with BlackRock for data centers and OpenAI's expanded compute collaboration with Cerebras. This comes as the stock experiences a notable dip, sparking widespread community debate over its "oversold" status and anticipation for its upcoming earnings report, particularly in the context of increasing AI data center energy costs and regulatory discussions.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending following significantly raised revenue targets for fiscal years and a substantially increased backlog, alongside a strong cash position fueling acquisition speculation. The community is highly engaged, anticipating further positive updates from the upcoming Investor Day and noting increased pressure on short sellers. Speculation also circulates around a potential spin-off of its autonomous systems division, adding to the buzz.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending following significant ERCOT approval, which doubled its Helios data center's power capacity to over 1.6 gigawatts for AI-hosting. The community views this as a pivotal moment, anticipating a re-rating of Galaxy as a key AI infrastructure provider with substantial future growth potential beyond its traditional crypto business.

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Regentis Biomaterials

Regentis Biomaterials (RGNT), a recent IPO, is rapidly trending following significant patent news for its GelrinC product, already approved in Europe. The community is actively discussing its extremely low float of 1.25 million shares and 180-day insider lock-up, fueling speculation about a potential short squeeze. Many are highlighting the company's 

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is surging amid reports of drastic price increases for its high-capacity 3D NAND and enterprise SSDs, fueled by explosive demand from the burgeoning AI infrastructure. This memory supercycle has propelled the stock to new highs, sparking a community debate between those who see it as an unstoppable market leader and others warning of an extreme valuation and potential bubble.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is generating significant buzz, driven by its unique optical interposer platform poised to revolutionize high-speed data transfer for AI and data centers. The community is actively discussing the recent acquisition of a key POET customer by a major semiconductor firm, which is widely seen as a strong validation of POET's underlying technology. This strategic move, coupled with expanding global partnerships, has ignited investor optimism for impending commercial milestones and robust order flow in the rapidly evolving photonics sector.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is generating buzz with its recent USD1 payroll and card integration via World Liberty Finance, alongside anticipation for its Super App launch and expanded blockchain integrations. The community is actively discussing ZBCN's advanced ISO 20022 compliance and its strategic positioning within the real-world asset sector, frequently comparing its potential to established players.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending with intense focus on its upcoming earnings report, as the community actively debates the implications of a potential all-cash offer for Warner Bros. Discovery assets and unconfirmed rumors of significant institutional buying. Investors are sharply divided, with some anticipating a substantial post-earnings rally from oversold levels, while others remain cautious due to acquisition-related uncertainties and recent stock performance. The market eagerly awaits clarity on both financial performance and the WBD deal's progression, driving high anticipation for the week ahead.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd is trending due to recent financial results indicating revenue growth in security-related engineering services and the anticipation of new contract news. The community is actively discussing its ultra-low share float and substantial short interest, leading to strong speculation about a potential short squeeze, drawing comparisons to other volatile 'Hong Kong low float' stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The trial compares Bacillus Calmette-Guérin (BCG) therapy alone with BCG combined with ANKTIVA.</li><li>Preliminary analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve cancer patients.</li><li>ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.</li></ul>ImmunityBio, Inc. (IBRX) shares jumped 24% in premarket trading on Friday after the company reported a faster than expected enrollment for its QUILT-2.005 bladder cancer drug trial.The company said that enrollment has surpassed internal expectations and is now more than 85% complete, with full enrollment of the planned study population expected by the second quarter of 2026.&nbsp;Based on current progress, ImmunityBio plans to submit a biologics license application to the U.S. Food and Drug Administration (FDA) by the end of 2026.“We look forward to the final accrual of this important registrational randomized trial in patients with BCG-naïve non-muscle-invasive bladder cancer, which represents a substantial proportion of newly diagnosed bladder cancer cases. The interim analysis is encouraging and consistent with findings in the approved BCG-unresponsive setting, where the duration of complete response has exceeded 47 months,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Medical and Scientific Officer of ImmunityBio.Based on current progress, ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.<h2 class="st-heading-2">What Is The Trial About?</h2>The QUILT-2.005 is a clinical trial for Bacillus Calmette-Guérin (BCG) naïve non-muscle-invasive bladder cancer (NMIBC) that compares standard BCG therapy alone versus BCG combined with ANKTIVA, an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.In 2023, the FDA requested an interim analysis of the randomized trial to evaluate the added benefit of ANKTIVA when combined with BCG, focusing on complete response rates and the durability of response versus BCG alone.The analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve NMIBC patients. At six months, 85% of patients receiving the combination maintained a complete response, compared with 57% in the BCG-only group. At nine months, response rates were 84% with combination therapy versus 52% with BCG alone.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_3d2f27a76b.webp" alt="IBRX.jpg">One user was bullish about the company’s potential.<stembedurl>https://stocktwits.com/Amit18/message/642024906</stembedurl>Another user saw the stock as a long-term runner.<stembedurl>https://stocktwits.com/LeftyT/message/642025351</stembedurl>Over the past year, the stock has gained more than 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-set-for-all-time-high-morgan-stanley-boost/cmUlAaBR4B7">RKLB Stock Is On Track For Record Open – Here’s What’s Driving The Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today 

The company said that enrollment for its randomized registrational QUILT-2.005 trial has surpassed internal expectations and is now more than 85% complete.

 IBRX Stock Rallies As Its Bladder Cancer Study Nears Full Enrollment 

Equity

<ul class="summary-bullets"><li>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa.</li><li>The company will also partner with regional pharmaceutical firm BioPharma Cigalah.</li><li>Enrolment for the QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter.</li></ul>ImmunityBio, Inc. (IBRX) drew retail attention on Wednesday as the stock jumped 8% after the Saudi Food and Drug Authority approved ANKTIVA in combination with the BCG (Bacillus Calmette-Guérin) vaccine to treat adults with BCG-unresponsive non-muscle invasive bladder cancer.The approval marks a major regulatory milestone, adding to existing authorizations in the United States and the United Kingdom, as well as conditional approval in the European Union.“We are pleased to bring ANKTIVA to Saudi patients with NMIBC, who otherwise have no viable options but life-altering surgery,” said Rich Adcock, Chief Executive Officer, ImmunityBio.<h2 class="st-heading-2">ImmunityBio’s Expansion Plans</h2>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa. The company will also partner with regional pharmaceutical firm BioPharma Cigalah. Management cited the rising incidence of bladder and other cancers in the region as a key driver behind the strategy.ANKTIVA is an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.<h2 class="st-heading-2">ANKTIVA Developments</h2>Beyond bladder cancer, ANKTIVA is also drawing attention for its broader oncology potential. <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-surge-today/cmUXXCjR4Ig">Recent clinical data</a> from the QUILT-2.023 and QUILT-3.055 trials in non-small cell lung cancer (NSCLC) showed improved immune recovery and extended survival when ANKTIVA was combined with checkpoint inhibitors.Responding patients achieved a median survival of up to 21.1 months, significantly outperforming traditional chemotherapy outcomes.Meanwhile, enrolment for the company’s QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter (Q2) of 2026 and a potential biologics license application (BLA) by the end of the year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around ImmunityBio remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_1a3db9b5f3.webp" alt="IBRX.jpg">One user speculated that the approval could double the product revenue for the company.<stembedurl>https://stocktwits.com/Bc3345/message/641787673</stembedurl>One user sees the stock climb to $5 in the short term and $15-25 in the medium term.<stembedurl>https://stocktwits.com/AshvsEvilDead/message/64178170</stembedurl><a href="https://stocktwits.com/AshvsEvilDead/message/641781706">6</a>Over the past year, <a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> have risen around 21%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-clsk-stock-rising-premarket-texas-data-centre-deal/cmULgA7R4e0">CLSK Stock Receives Premarket Boost On Texas Data Center Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval

The approval in Saudi Arabia follows authorizations in the U.S. and the U.K., as well as a conditional approval in the European Union.

<ul class="summary-bullets"><li>The move is a major step toward FDA approval of NRX-100, its investigational drug.</li><li>Currently, no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.</li><li>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting.</li></ul>NRx Pharmaceuticals, Inc. (NRXP) on Wednesday announced that it has licensed Real World Evidence (RWE) from more than 70,000 U.S. patients who received either intravenous ketamine or nasal S-ketamine as part of their treatment.The move is a major step toward FDA approval of its investigational drug, NRX-100 (preservative-free ketamine), aimed at treating suicidal ideation in patients with depression and suicidal tendencies.&nbsp;<h2 class="st-heading-2">Collaboration With Osmind</h2>The RWE data comes from Osmind, a neuropsychiatry technology platform used across U.S. clinics, providing detailed, regulatory-grade patient records. This joint effort allows NRx to submit a comprehensive dataset to the FDA in support of Accelerated Approval for NRX-100 under its Fast Track Designation.&nbsp;The approach could mark a breakthrough, as currently no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals' stock&nbsp;</a>traded over 21% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ territory from ‘bearish’ the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Preliminary Findings And Expectations</h2>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting. Results suggested rapid improvement in depression and suicidal ideation with intravenous ketamine.&nbsp;NRx anticipates that analysis of the full 70,000-patient dataset will provide even stronger evidence to support the FDA submission.<blockquote>“An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials.”-Jonathan Javitt, Chairman and CEO, NRx Pharmaceuticals</blockquote>NRXP stock has declined by over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a hand holding a medical syringe seen displayed in front of the NRx Pharmaceuticals logo.

Why Did NRXP Stock Surge 21% Pre-Market Today?

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.

<ul class="summary-bullets"><li>The company said that responding patients lived longer overall, with a median survival of 16.2 months.</li><li>The data come from two clinical trials, evaluating 151 patients across first-line and later-line treatment settings.</li><li>ImmunityBio is now advancing its Phase 3 trial, it said.</li></ul>ImmunityBio Inc. (IBRX) stock caught retail attention on Tuesday after the company reported positive clinical results showing its immunotherapy ANKTIVA significantly boosts immune function and improves survival in non-small cell lung cancer (NSCLC) patients when combined with checkpoint inhibitors.The data come from two clinical trials, QUILT-2.023 and QUILT-3.055, evaluating 151 patients across first-line and later-line treatment settings.<a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> were up 12.4% at the time of writing. Retail chatter increased to ‘high’ on Stocktwits while sentiment shifted to ‘extremely bullish’ from ‘bullish’ a day earlier.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_72f59b2252.webp" alt="IBRX.jpg">One bullish user expects the U.S. Food and Drug Agency (FDA) to approve ANKTIVA for NSCLC and expand access broadly.<stembedurl>https://stocktwits.com/svertical1/message/641645369</stembedurl>Another user sees the benefits of a non-chemotherapy treatment.<stembedurl>https://stocktwits.com/Armymike1981/message/641633526</stembedurl><h2 class="st-heading-2">Outcome Of The Trials</h2>In the first-line QUILT-2.023 study, patients receiving ANKTIVA plus a checkpoint inhibitor showed a statistically significant and sustained increase in absolute lymphocyte count (small white blood cell) compared with checkpoint inhibitor therapy alone. In the second- and later-line QUILT-3.055 study, 77% of patients maintained or restored healthy lymphocyte levels, showing ANKTIVA’s role as a lymphocyte-stimulating agent.The company said that responding patients lived longer overall, with a median survival of 16.2 months, while those with stronger immune recovery had a median survival of 21.1 months, far exceeding historical results with standard chemotherapy.ImmunityBio is now advancing its Phase 3 trial, comparing ANKTIVA plus checkpoint inhibitors to docetaxel in second-line NSCLC, it added.“The results from these studies support a potential paradigm shift toward what we define as Immunotherapy 2.0, which is the coordinated activation of the innate immune system through natural killer cells and the adaptive immune system through T cells to restore immune competence and extend survival,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio.Over the past year, IBRX shares have gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-q4-revenue-beat-apple-card-reserve-hits-profit/cmUXEfbR44r">JPMorgan Beats Revenue Estimates In Q4 – A Record Quarter For Wealth Unit Offsets Apple Card Drag</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients

The company reported positive results with ANKTIVA, which boosted immune function and improved survival in NSCLC when combined with checkpoint inhibitors.

<ul class="summary-bullets"><li>Travere said its responses are currently under agency review.</li><li>FDA’s PDUFA target action date for full approval of Filspari in Focal Segmental Glomerulosclerosis is January 13.</li><li>The company expects U.S. net product sales of about $127 million in Q4 and about $410 million for the full year 2025.</li></ul>Shares of Travere Therapeutics Inc.&nbsp;(TVTX) slumped 30% in premarket trading on Tuesday after the company said the U.S. Food and Drug Administration (FDA) requested additional information to assess Filspari’s clinical benefit.Travere said its responses are currently under agency review. Filspari is a treatment for adults with primary immunoglobulin A nephropathy, a progressive kidney disease that can ultimately lead to kidney failure.FDA’s PDUFA (Prescription Drug User Fee Act) target action date for full approval of Filspari in Focal Segmental Glomerulosclerosis (FSGS) is January 13. A PDUFA date is the FDA's target date to make a decision on a drug application. If approved, Filspari would be the first treatment for FSGS, and the company says it is well-positioned for a commercial launch.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp premarket decline, retail sentiment on Stocktwits changed to ‘extremely bullish’ from ‘bullish’ a day back, accompanied by ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/TVTX">TVTX</a> was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/TVTX_jpg_74da780cfd.webp" alt="TVTX.jpg">One user said that the FDA’s request is ‘very common’.<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/641602359</stembedurl>However, one bearish user was skeptical about the timelines.<stembedurl>https://stocktwits.com/Aawilliam2003/message/641609384</stembedurl><h2 class="st-heading-2">2026 Outlook</h2>Travere Therapeutics provided an update on its sales outlook for the fourth quarter and full year 2025. The company expects U.S. net product sales of about $127 million in the fourth quarter (Q4) and about $410 million for the full year, based on preliminary and unaudited results. Travere ended 2025 with around $323 million in cash, cash equivalents, and marketable securities.Clinically, the company plans to advance clinical evidence supporting FILSPARI as a foundational treatment for IgA nephropathy, also known as Berger's disease, a chronic kidney ailment. Its partner, Chugai Pharmaceutical, is expected to submit a New Drug Application (NDA) for Sparsentan in Japan next year.Meanwhile, the company is on track to restart Phase 3 HARMONY Study of Pegtibatinase in classical homocystinuria (HCU), a genetic metabolic disorder, in the first quarter of 2026 following manufacturing process improvements.The stock has seen significant buying interest over the past year, gaining nearly 90%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-nvts-stock-gaining-retail-attention-ai-power-play/cmUXcZPR44k">NVTS Stock Draws Retail Interest On AI Data Center Power Play</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did TVTX Stock Crash 30% In Pre-Market Today?

Shares of Travere Therapeutics Inc. (TVTX) slumped 30% in premarket trading on Tuesday after the company said the U.S. Food and Drug Administration (FDA) requested additional information to assess Filspari’s clinical benefit.

The U.S. Food and Drug Administration recently requested additional information to assess Filspari’s clinical benefit.

Here's Why Biotech ETFs Are Rallying Hard 

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

<ul class="summary-bullets"><li>The company reported 64% overall survival at 12 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP.</li><li>The combination showed 94% and 83% overall survival at 6 months and 9 months.</li><li>Immuneering is now looking to start dosing the first patient in the pivotal late-stage trial in mid-2026.</li></ul>Immuneering Corporation (IMRX) on Wednesday said that its experimental drug improved overall survival in a mid-stage trial in patients with first-line pancreatic cancer, causing the stock to close 24% higher.The company was studying atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP). The company reported 64% overall survival at 12 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP, compared to a 35% overall survival rate observed in patients given standard of care treatment.The combination showed 94% and 83% overall survival at 6 months and 9 months, both higher than the survival rate seen in patients receiving standard of care. The company also confirmed an overall response rate of 39% at 12 months for the combination, compared to 23% response rate in standard of care patients. Overall Survival (OS) in cancer is the length of time from diagnosis or start of treatment until death from any cause, serving as the "gold standard" measure for a treatment's effectiveness by showing if it helps patients live longer.&nbsp;However, no head-to-head clinical trial has been conducted evaluating atebimetinib and other candidates or products, the company clarified.<h2 class="st-heading-2">Safety Concerns</h2>Atebimetinib + mGnP continued to demonstrate a favorable tolerability profile in the patient population in the trial, with only two categories of adverse events observed at the Grade 3 level, the company said. No new safety signals were identified.The company is now looking to start dosing the first patient in the pivotal late-stage trial in mid-2026. In the latter half of the year, the company is also looking to dose the first patient with atebimetinib in combination with Libtayo in non-small cell lung cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IMRX stayed at ‘extremely bullish’ levels while message volume rose ‘high’ to ‘extremely high' levels.&nbsp; <a href="https://stocktwits.com/symbol/IMRX">IMRX stock</a> has gained nearly 253% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/revolution-medicines-stock-soars-on-report-of-abbvie-takeover/cmxzObIR42q">Revolution Medicines Stock Drops After-Hours On AbbVie Denying Acquisition Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Immuneering logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IMRX Stock Closed Over 20% Higher Today: Here’s Why

The company was studying atebimetinib in combination with modified gemcitabine/nab-paclitaxel. 

<ul class="summary-bullets"><li>94% of participants achieved CRP levels below 2 mg/L, a threshold associated with lower cardiovascular risk.</li><li>Safety data were favorable, with adverse events that were mild to moderate, self-resolving, and not dose-dependent.</li><li>The company expects partner Novartis to begin multiple Phase 2 studies of MRT-6160 in immune-mediated diseases.</li></ul>Shares of Monte Rosa Therapeutics (GLUE) surged more than 50% in pre-market trading on Wednesday after the company reported positive interim Phase 1 data for MRT-8102, highlighting strong anti-inflammatory effects in subjects with elevated cardiovascular disease risk.<a href="https://stocktwits.com/symbol/GLUE">GLUE stock</a> is on track to open at its highest level in more than four years.<h2 class="st-heading-2">Phase – 1 Highlights</h2>The NEK7-directed molecular glue degrader produced rapid and durable reductions in systemic inflammation, with C-reactive protein (CRP) levels falling by 85% after four weeks of treatment. Notably, 94% of participants achieved CRP levels below 2 mg/L, a threshold associated with lower cardiovascular risk.The randomized, placebo-controlled study included single and multiple ascending doses, as well as a Part 3 cohort enrolling subjects with obesity and elevated CRP. Across doses ranging from 5 mg to 400 mg, MRT-8102 demonstrated deep and sustained NEK7 degradation of roughly 80% to 90%.&nbsp;The treatment also led to significant reductions in inflammatory markers. Safety data were favorable, with adverse events that were mild to moderate, self-resolving, and not dose-dependent, and no increased risk of infection was observed.Based on these results, Monte Rosa has expanded the ongoing GFORCE-1 study to multiple dose levels, with additional data expected in the second half of 2026. The company plans to initiate a Phase 2 study in atherosclerotic cardiovascular disease later this year, while continuing to explore additional inflammatory and oncology indications.Monte Rosa also outlined several upcoming milestones across its immunology, inflammation, and oncology programs. It expects partner Novartis to begin multiple Phase 2 studies of MRT-6160 in immune-mediated diseases and plans to submit an investigational new drug (IND) application&nbsp;for a next-generation NEK7 program in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes. GLUE was among the top trending tickers on the platform.<figure class="image"><img src="https://news.stocktwits-cdn.com/GLUE_jpg_c79d022259.webp" alt="GLUE.jpg" width="937" height="99"><figcaption>GLUE's Sentiment Meter and Message Volumes at Premarket on Jan. 7, 2026 | Source: Stocktwits</figcaption></figure>One user sees a strong rally if the stock can overcome resistance at $28.<stembedurl>https://stocktwits.com/MuchMillions/message/641056765</stembedurl>Over the past year, the stock has gained more than 120%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-first-solar-stock-fall-5-in-premarket-today/cmxyC2bR4cD">Why Did First Solar Stock Fall 5% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did GLUE Stock Surge Over 50% In Premarket Today?

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

SPDR Series Trust - State Street SPDR S&P Biotech ETF

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

SPDR S&P Biotech ETF

Biotech sector primed for an M&A surge, driven by expiring big pharma patents and strong capital inflows into undervalued innovative companies.

Optimism is growing for a biotech rebound in 2026, fueled by rising IPO interest, lower interest rates, and strong momentum after a 33% gain in 2025.

Regulatory actions are a mixed bag for biotech, with new FDA guidances providing tailwinds while some companies face setbacks like Complete Response Letters.

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XBI News

XBISPDR S&P Biotech ETF